Bionano Genomics, Inc. filings document the formal disclosures of a genome-analysis company commercializing optical genome mapping solutions, diagnostic testing services, genome-analysis software and nucleic acid extraction and purification technologies. Form 8-K reports record financial results, preliminary results, material agreements, securities offerings and executive leadership changes, while registration statements describe offered common stock, pre-funded warrants and warrant securities.
Proxy materials cover board elections, executive compensation, equity-award matters, shareholder voting and governance practices. The filing record also documents capital-structure changes, Nasdaq-listed common stock disclosures, risk factors and exhibits tied to Bionano’s OGM, VIA software, Ionic system and Bionano Laboratories operations.
OLDAKOWSKI MARK reported acquisition or exercise transactions in this Form 4 filing.
Bionano Genomics reported a Form 4 for Chief Operating Officer Mark Oldakowski showing a grant of 15,000 stock options to buy common stock at $1.12 per share, expiring in 2036. The options vest 50% on each of the first two anniversaries of the vesting commencement date, subject to continuous service.
Bionano Genomics, Inc. reported an equity award to Chief Scientific Officer Alex Reid Hastie of a stock option covering 54,000 shares of common stock at an exercise price of $1.12 per share, expiring August 2, 2036. Twenty-five percent vests August 2, 2027, with the balance vesting in 36 monthly installments, and the report replaces an earlier erroneous initial ownership statement filed August 5, 2026.
Bionano Genomics, Inc. reports that Chief Operating Officer Mark Oldakowski beneficially owns a stock option giving the right to buy 15,000 shares of Common Stock at an exercise price of $1.12 per share. The option expires on August 2, 2036. According to the equity plan footnote, the shares subject to the option vest 50% of the total on each of the first and second anniversaries of the vesting commencement date, in each case conditioned on the executive’s Continuous Service, as defined in the company’s 2018 plan. The position is reported as direct ownership.
Bionano Genomics, Inc. reports that Principal Accounting Officer Mark Adamchak holds a stock option covering 5,000.0000 shares of common stock at an exercise price of 1.1200 per share, expiring on 2036-08-02. The option vests 50% on each of the first and second anniversaries of the vesting commencement date, subject to his Continuous Service under the company’s 2018 Plan.
Bionano Genomics, Inc. reports that Chief Scientific Officer Hastie Alex Reid holds a stock option (right to buy) covering 54,000 shares of Common Stock at an exercise price of $1.12 per share, with an expiration date of August 2, 2036.
According to the vesting terms, 25% of the option shares vest and become exercisable on August 2, 2027, and the remaining shares vest in 36 equal monthly installments thereafter, subject to his Continuous Service under the company's 2018 Plan.
Bionano Genomics, Inc. insider Jonathan V. Dixon, the company’s General Counsel, holds a stock option classified as a derivative security. The option covers 15,000 shares of Common Stock at an exercise price of $1.1200 per share and expires on August 2, 2036.
The shares subject to this option vest 50% on each of the first and second anniversaries of the vesting commencement date, in each case subject to Mr. Dixon’s Continuous Service under the company’s 2018 Plan.
Bionano Genomics, Inc. reported initial insider ownership for Chief Scientific Officer Alex Reid Hastie. The filing lists direct beneficial ownership of 63 shares of Common Stock, with no insider purchases or sales reported in this Form 3 statement.
Bionano Genomics, Inc. announced the appointment of Alex Hastie, Ph.D. as Chief Scientific Officer, effective July 20, 2026. He will lead global scientific strategy, innovation, and research initiatives focused on expanding applications of the company’s optical genome mapping (OGM) technologies in research and clinical genomics.
Hastie previously spent 14 years at Bionano and was a key contributor to the development of its core OGM platforms. Several leading academic and clinical genomics experts are quoted expressing strong support for his return, highlighting his deep expertise and long-standing role in advancing OGM.
Bionano Genomics, Inc. reported that its Chief Medical Officer, Alka Chaubey, Ph.D., has resigned. The resignation was submitted on June 2, 2026 and will be effective July 5, 2026. The company is incorporated in Delaware and its common stock trades on the Nasdaq Capital Market under the symbol BNGO.
Bionano Genomics, Inc. general counsel Jonathan V. Dixon reported a routine tax-related share withholding. When a restricted stock unit (RSU) award vested on June 3, 2026, the company withheld 24 shares of common stock at $1.30 per share to cover tax obligations. After this non-market disposition, Dixon directly holds 239 common shares.